Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 23%
Hold 38%
Sell 8%
Strong Sell 0%

Bulls say

Incyte has demonstrated significant revenue growth, primarily driven by a 10% year-over-year increase in demand for its leading drug Jakafi along with a successful commercial launch of Niktivmo. The company also reported strong performance from Opzelura, with revenue exceeding consensus expectations at $188 million due to heightened patient demand for atopic dermatitis and vitiligo treatments. Incyte's raised guidance for FY25 to $4.23 billion - $4.32 billion, bolstered by Jakafi and other oncology products, underscores the firm's positive momentum and continued market opportunities.

Bears say

Incyte's stock faces a negative outlook primarily due to eroding pricing power for its leading drug, Jakafi, which treats rare blood cancers and graft versus host disease, suggesting potential challenges in maintaining revenue growth. Additionally, the performance of the earlier-stage pipeline appears to be lacking, with risks associated with clinical and regulatory setbacks that could hinder product launches and market acceptance. Furthermore, concerns regarding market competition, safety signals from marketed products, and general uptake challenges underscore the volatility and uncertainty surrounding Incyte's future financial performance.

Incyte (INCY) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 23% recommend Buy, 38% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 13 analysts, Incyte (INCY) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $93.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $93.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.